Glycopeptide Antibiotics Market Outlook Highlights The Next Major Growth Opportunities
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Glycopeptide Antibiotics Market Growth Potential: How Will Market Size Change Through 2030?
Over the recent period, the glycopeptide antibiotics market has experienced robust expansion, with projections indicating it will rise from $3.78 billion in 2025 to $4.13 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.0%. This past growth has been driven by factors such as a higher incidence of hospital-acquired infections, the extensive use of vancomycin as a primary treatment, an increasing number of gram-positive bacterial infections, the scarcity of other antibiotic options, and the growth of inpatient healthcare facilities.
The glycopeptide antibiotics market is anticipated to experience significant expansion over the coming years, projected to reach $5.89 billion by 2030 with a compound annual growth rate (CAGR) of 9.3%. This upward trajectory during the forecast period is driven by factors such as the proliferation of multidrug-resistant pathogens, greater uptake of long-acting glycopeptides, increased need for outpatient and home-based antibiotic treatments, ongoing research and development in next-generation glycopeptides, and rising global healthcare spending. Key trends shaping this period include a growing reliance on glycopeptides to combat resistant infections, an expanding array of lipoglycopeptide antibiotic products, higher intravenous glycopeptide usage in hospital settings, enhanced emphasis on optimized dosing and therapeutic monitoring, and broader application in managing severe gram-positive infections.
Download A Free Sample Report For Comprehensive Market Insights:
Glycopeptide Antibiotics Market Growth Drivers: What Factors Are Accelerating Expansion?
The anticipated expansion of the glycopeptide antibiotic market over the coming years is largely driven by the rising incidence of gram-positive infections. These infections, caused by bacteria such as Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes, are effectively targeted by glycopeptide antibiotics, which work by disrupting bacterial cell wall synthesis. A clear example of this trend is highlighted in the Group A Streptococcal Infections: Report on Seasonal Activity in England 2022–2023, published in June 2023 by the UK Health Security Agency, a government entity responsible for safeguarding public health and managing infectious diseases. The report revealed a significant increase in invasive Group A Streptococcus (iGAS) cases, with 509 laboratory-confirmed notifications by week 46 of 2023 and a weekly high of 73 cases. This surge reflects a growing burden of infectious diseases, which in turn amplifies the need for potent antimicrobial therapies within healthcare systems. Consequently, the escalating prevalence of gram-positive infections serves as a key factor propelling the glycopeptide antibiotic market forward.
Glycopeptide Antibiotics Market Segment Landscape And Growth Potential
The glycopeptide antibiotics market covered in this report is segmented –
1) By Drug: Vancomycin, Dalbavancin, Oritavancin, Other Drugs
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By Indication: Skin And Structure Infection, Meningitis, Clostridioides Difficile Infection, Enterocolitis, Other Indications
4) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Vancomycin: Vancomycin Injection, Vancomycin Oral Solution, Vancomycin Capsules, Vancomycin Powder for Solution
2) By Dalbavancin: Dalbavancin IV (Intravenous) Formulation, Dalbavancin Powder for Injection
3) By Oritavancin: Oritavancin IV (Intravenous) Formulation, Oritavancin Powder for Injection
4) By Other Drugs: Teicoplanin, Glycopeptide and Lipoglycopeptide Antibiotics
Glycopeptide Antibiotics Market Trends: What Is Shaping Future Industry Growth?
Major players in the glycopeptide antibiotics market are prioritizing the creation of advanced products, including innovative glycopeptide scaffolds, to secure an edge over their competitors. These scaffolds are antibiotic frameworks with distinct structural features, developed through cutting-edge biosynthetic methods or natural product discovery. In May 2025, for instance, a Chinese-European research team, leveraging expertise from both regions, unveiled Saarvienin A—a novel glycopeptide characterized by a halogenated peptide core, an unusual ureido linkage, and five unique sugar or aminosugar components. Unlike conventional glycopeptides, Saarvienin A does not target the typical cell-wall site, suggesting it operates through a potentially new mechanism, and it demonstrates strong in vitro efficacy against resistant Gram-positive bacteria, including MRSA and vancomycin-resistant Enterococcus. Although this breakthrough represents a significant advancement in combating antibiotic resistance, it must overcome hurdles such as clinical development, safety optimization, and production scaling.
Glycopeptide Antibiotics Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the glycopeptide antibiotics market are ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Novartis AG, Hikma Pharmaceuticals Plc., Aurobindo Pharma Limited, Abbvie Inc., Cumberland Pharmaceuticals Inc., Janssen Global, Bristol-Myers Squibb Company, Shenwei Pharmaceutical Hainan Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Alvogen, Bayer AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Sanofi SA, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Inc.
Access The Complete Glycopeptide Antibiotics Market Report:
Glycopeptide Antibiotics Market Geographic Distribution And Regional Opportunities
North America was the largest region in the glycopeptide antibiotics market in 2025. The regions covered in the glycopeptide antibiotics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
